Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Camber Capital Surges Stake In Sequenom Inc. (SQNM) To Over 5%

Camber Capital Management, managed by Stephen Dubois, is bullish on Sequenom Inc. (NASDAQ:SQNM). In a new filing with the Securities and Exchange Commission, Camber Capital disclosed a 5.41% passive stake in the company, containing 6.30 million shares, up from 2.91 million shares held previously.

Sequenom, Inc. (NASDAQ:SQNM)

Sequenom Inc. (NASDAQ:SQNM) is a life sciences company engaged in improving healthcare through revolutionary genomic and genetic analysis solutions. The company has a market cap of $422.5 million. At the end of last month, the company said it completed the sale of its Bioscience business to Agena Bioscience, a portfolio company of Telegraph Hill Partners. Under the agreement, Sequenom Inc. (NASDAQ:SQNM) will receive $31.8 million, subject to certain adjustments, and may also receive up to $4 million in contingent consideration upon the achievement of certain regulatory and sales milestones, according to a statement.

For the first quarter of 2014, the company posted a net loss of $15.7 million, or $0.13 per share, compared to net loss of $29.4 million, or $0.26 per share, for the same period of 2013. Adjusted net loss for the first quarter was $14.7 million, or $0.13 per share. The company reported revenue of $46.3 million for the first quarter, representing an increase of 20% compared to revenue of $38.5 million for the first quarter of 2013. Revenues from diagnostic services was up 27%, compared to the first quarter of 2013, and 13% on a sequential basis over the fourth quarter of 2013.

On Monday, the company’s stock rose 0.97% to $3.62. It has a 52 week high of $4.90 and a 52 week low of $1.65. The consensus average target price is $4.63 on the stock, while the consensus average recommendation is ‘overweight.’

In addition to Camber Capital, other significant shareholders of Sequenom Inc. (NASDAQ:SQNM) include William Leland Edwards‘ Palo Alto Investors and Youlia Miteva’s Proxima Capital Management, owning 9.79 million shares and 2.21 million shares, respectively.

Disclosure: none

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!